The majority of studies have focused on chronic myeloid leukemia (CML) and JAK2-mutant MPN (Hu et al., 2011; Gandre-Babbe et al., 2013; Kumano et al., 2012; Hosoi et al., 2014; Ye et al., 2014; Suknuntha et al., 2015; Sloma et al., 2017; Mulero-Navarro et al., 2015; Miyauchi et al., 2018; Amabile et al., 2015; Ye et al., 2009b). Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.